

REAL WORLD. REAL VALUE.

Breakout Session 1:Post-Marketing Programs – a (mostly) European Perspective

Basel, May 5, 2008

Post-Marketing Program Characteristics:

- Following a product's introduction into the marketplace (Phase IV) – initiation can take place before launch
- In the real-life setting of day-to-day routine clinical practice
- In larger and heterogeneous patient populations
- Data assessments commonly follow routine practice, i.e. no prescribed interventions, reduced burden on physicians and patients (study drugs generally not financed by sponsor)
- Overall study procedures tend to be less rigorous than in clinical research (non GCP compliant). *Exceptions*: patient consent, data confidentiality, adverse event reporting
- Audiences for post-marketing real-life data include all the major players in healthcare: physicians, patients, payers and regulatory as well as pricing/reimbursement authorities



The Marketing Program "Continuum"

Phase IV "Studies"

Hybrid "Projects"

Value Added "Programs"

Controlled, comparative head-to-head studies

New indications / Labeling changes

Surveillance studies

Physician/Patient Surveys

PRO/HRQoL/Outcomes/ Economic studies

Patient/Disease registries

Patient/Physician education programs

Compliance / loyalty programs

➤ Where you position your study depends on your diverse strategic objectives




Data from Post-Marketing Programs are typically used to:

- Convince regulatory authorities that the product is safe in broad, heterogeneous patient populations
- Convince physicians of the product's effectiveness and value in clinical practice, in their own patients
- Expand and prepare the marketplace and support a new compound's launch
- Convince patients of the product's benefits for them personally and to use the product appropriately and regularly (compliance), to achieve an optimum of therapeutic benefit and tolerability
- Obtain and maintain reimbursement, both in terms of the reimbursed indication(s), the market price, and – in the longer term – to defend against the erosion of price and reimbursement




Business-Objectives ⇒ Rx Growth, increase in market share, minimal time to peak sales......






Dilemma ⇒ **Drop Outs**



Source: I. Arnet et al, Kantonsspital Basel. "Überzeugung als Fundament der Compliance und Techniken zur Compliance Optimierung." Schweiz Med Wochenschrift 1999; 129:1477-86 Peer reviewed article




Business Objectives of Post-Marketing Programs






Post Marketing Program Return on Investment: one Key to "selling" Programs Internally



> Identifying and recruiting the right patients



Physician Participation in Post Marketing Programs



> Identifying and recruiting the right physicians



Proposed Case Studies

- Expanding the US Osteoporosis Market N.O.R.A.
- Launch of an innovative compound in Pulmonary Arterial Hypertension (PAH) *The PAH Online Registry*
- Satisfying EMEA risk mapping and safety monitoring demands - The PAH Online Registry
- Building a European Franchise in Multiple Sclerosis -MyMSLine
- Maintaining reimbursement by demonstrating optimal onlabel use of a novel metabolism compound – a pan-European drug utilization Registry
- A (failed) attempt to corner the Cox2 market in Germany a PRO survey program
- Optionally: additional case studies or challenges presented by members of the group

